Wall Street analysts predict that CVS Health Corp (NYSE:CVS) will post earnings per share of $2.12 for the current quarter, Zacks reports. Nineteen analysts have made estimates for CVS Health’s earnings. The highest EPS estimate is $2.19 and the lowest is $2.00. CVS Health reported earnings per share of $1.92 in the same quarter last year, which indicates a positive year-over-year growth rate of 10.4%. The company is expected to issue its next earnings report on Thursday, February 14th.
According to Zacks, analysts expect that CVS Health will report full year earnings of $7.03 per share for the current financial year, with EPS estimates ranging from $6.90 to $7.07. For the next financial year, analysts forecast that the firm will post earnings of $7.39 per share, with EPS estimates ranging from $6.85 to $7.70. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for CVS Health.
CVS Health (NYSE:CVS) last issued its quarterly earnings results on Tuesday, November 6th. The pharmacy operator reported $1.73 earnings per share for the quarter, beating analysts’ consensus estimates of $1.71 by $0.02. CVS Health had a net margin of 1.65% and a return on equity of 18.69%. The firm had revenue of $47.27 billion during the quarter, compared to the consensus estimate of $47.22 billion. During the same period in the prior year, the firm earned $1.50 EPS. The business’s revenue was up 2.4% on a year-over-year basis.
Shares of CVS Health stock opened at $74.09 on Wednesday. The company has a quick ratio of 1.94, a current ratio of 2.44 and a debt-to-equity ratio of 1.66. CVS Health has a fifty-two week low of $60.14 and a fifty-two week high of $83.88. The firm has a market capitalization of $78.01 billion, a price-to-earnings ratio of 11.23, a P/E/G ratio of 1.10 and a beta of 0.98.
In other news, CFO David M. Denton sold 25,159 shares of the firm’s stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $80.13, for a total transaction of $2,015,990.67. Following the completion of the transaction, the chief financial officer now directly owns 403 shares of the company’s stock, valued at approximately $32,292.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Lisa Bisaccia sold 21,534 shares of the firm’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $80.00, for a total transaction of $1,722,720.00. The disclosure for this sale can be found here. Insiders have sold a total of 74,233 shares of company stock valued at $5,932,565 over the last ninety days. 0.53% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the company. Canton Hathaway LLC acquired a new stake in shares of CVS Health during the 3rd quarter worth about $126,000. MCF Advisors LLC increased its position in shares of CVS Health by 284.1% during the 3rd quarter. MCF Advisors LLC now owns 1,713 shares of the pharmacy operator’s stock worth $135,000 after purchasing an additional 1,267 shares in the last quarter. Capital Guardian Trust Co. acquired a new stake in shares of CVS Health during the 3rd quarter worth about $142,000. Patten Group Inc. increased its position in shares of CVS Health by 163.4% during the 3rd quarter. Patten Group Inc. now owns 1,844 shares of the pharmacy operator’s stock worth $145,000 after purchasing an additional 1,144 shares in the last quarter. Finally, Mainstay Capital Management LLC ADV acquired a new stake in shares of CVS Health during the 2nd quarter worth about $154,000. 84.50% of the stock is owned by institutional investors.
About CVS Health
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Further Reading: Quiet Period
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.